<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136318</url>
  </required_header>
  <id_info>
    <org_study_id>ML18075</org_study_id>
    <nct_id>NCT00136318</nct_id>
  </id_info>
  <brief_title>Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients</brief_title>
  <acronym>CIPPAD</acronym>
  <official_title>Efficacy and Tolerability of Escitalopram for the Prevention of Pegylated Interferon Alfa Associated Depression in Patients With Chronic Hepatitis C Infection: a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary end points

        -  incidence of depression defined as a Montgomery Asberg Depression Scale Score (MADRS) of
           13 or higher during antiviral therapy (up to 48 weeks, depending on genotype)

        -  effect of an antidepressive pre-treatment over two weeks and a continuously concomitant
           treatment with Escitalopram (S-citalopram) on frequency and severity of depression in
           patients with chronic hepatitis C (HCV) treated with Peg-interferon alfa-2a (PEGASYS)
           and ribavirin, measured by the Montgomery Asberg Depression Scale

      Secondary end points

        -  time to depression defined as a MADRS score of 13 or higher

        -  incidence of major depression defined by Diagnostic and Statistical Manual IV (DSM-IV)
           criteria

        -  severe depression according to MADRS scale (score 25 or higher)

        -  Health related quality of life (HRQOL) measured by the Short Form 36 (SF-36)

        -  sustained virologic response

        -  tolerability

        -  safety

        -  changes/group differences in other psychiatric depression scales (Hamilton Depression
           Rating Scale, Beck Depression Inventory)

      Other investigations:

        -  cognitive function, anxiety (word fluency test, trail making test part A and B, othe
           scales)

        -  Predictive parameters for patients especially gaining from an antidepressive therapy
           (e.g. age, gender, weight, height, alanine aminotransferase (ALAT) quotient defined as
           median ALAT values before treatment divided by the upper standard value, HCV-RNA serum
           concentration level of fibrosis in liver histology, baseline values of the different
           psychometric scales)

        -  alanine aminotransferase (ALAT), aspartate transaminase (ASAT), thyrotrophin (TSH)

        -  biomarkers (genetic parameters, cytokines,...)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Scale (MADRS) With a Score of 13 or Higher</measure>
    <time_frame>50 weeks for genotypes 1 or 4 and 26 weeks for patients with genotype 2 or 3</time_frame>
    <description>Clinically relevant depression (MADRS score of 13 or higher) during antiviral treatment presented as &quot;percentage of participants&quot; with &quot;MADRS scores &gt; 13&quot; (entire time period: from starting study medication until end of antiviral treatment = 48 weeks in patients with genotype 1 or 4 and 24 weeks for patients with genotype 2 or 3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Without Depression (Defined as a MADRS Score of 13 or Higher)</measure>
    <time_frame>Patients free of depression during 24 or 48 weeks of antiviral therapy</time_frame>
    <description>Number of patients who did not develop at any time of antiviral treatment (up to 48 weeks) a MADRS score of 13 or more as a sign of clinically relevant depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Depression Defined by Diagnostic and Statistical Manual IV (DSM-IV) Criteria</measure>
    <time_frame>major depression during 24 or 48 weeks of antiviral therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Depression Defined as a MADRS Score of 25 or Higher</measure>
    <time_frame>severe depression during 24 or 48 weeks of antiviral therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQOL) Measured by the Short Form 36 (SF-36)</measure>
    <time_frame>assessed 2,4,12,24 and 48 weeks of antiviral treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>assessed 24 weeks after end of antiviral treatment</time_frame>
    <description>(negative Polymerase Chain Reaction (PCR) 6 months after the end of antiviral treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>assessed 2,4,12,24 and for genotype 1 and 4, 48 weeks of antiviral treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>assessed 2,4,12,24 and for genotype 1 and 4, 48 weeks of antiviral treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <arm_group_label>Escitalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PEG-IFN alfa-2a</other_name>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis C infection defined as positive anti-HCV antibodies and serum
             HCV-RNA &gt;1000 IU/ml, naive to antiviral treatment

          -  age &gt;18 years

        Exclusion Criteria:

          -  Antidepressive treatment within the last 3 years

          -  Psychiatric diseases including major depressive disorders in past medical history

          -  Active substance abuse during the last 12 months

          -  Pregnancy, lactation, wish to become pregnant

          -  Hepatitis B (HBV)/HIV-coinfection

          -  Decompensated liver disease, hepatocellular carcinoma, history of bleeding esophageal
             varices

          -  Neutropenia (&lt;1500/ul), thrombocytopenia (&lt;70/nl), anemia (&lt;12g/dl in females, &lt;13g/dl
             in males)

          -  History of autoimmune disease

          -  History of organ transplantation, concomitant liver disease, severe cardiopulmonary
             disease, hemolytic anemia, malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Berg, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Charité</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Schaefer, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterolgy and Rheumatology, Sektion Hepatology</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <results_first_submitted>October 25, 2012</results_first_submitted>
  <results_first_submitted_qc>March 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 21, 2013</results_first_posted>
  <last_update_submitted>March 20, 2013</last_update_submitted>
  <last_update_submitted_qc>March 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>M. Schaefer, MD</investigator_full_name>
    <investigator_title>Martin Schaefer, MD</investigator_title>
  </responsible_party>
  <keyword>Pegasys-Induced depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 208 of the 300 patients screened were enrolled between August 2004 and September 2008 in different centers in the pre-observation period. Overall 181 patients started the treatment period by taking escitalopram or placebo.</recruitment_details>
      <pre_assignment_details>A total of 208 of the 300 patients screened were enrolled between August 2004 and September 2008. 92 patients did not meet the inclusion criteria, had exclusion criteria or did not want to participate in the trial.27 patients stopped the trial during the preobservation period before the trial started by taking antidepressant or placebo therapy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Escitalopram</title>
          <description>After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
Peginterferon alfa-2a :
Escitalopram :
Ribavirin :</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
Peginterferon alfa-2a :
Placebo :
Ribavirin :</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90">Took first dose of study medication</participants>
                <participants group_id="P2" count="91">Took first dose of study medication</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83">reached end-point of antiviral treatment</participants>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Escitalopram</title>
          <description>After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
Peginterferon alfa-2a :
Escitalopram :
Ribavirin :</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
Peginterferon alfa-2a :
Placebo :
Ribavirin :</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="91"/>
            <count group_id="B3" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="11"/>
                    <measurement group_id="B2" value="48.5" spread="11"/>
                    <measurement group_id="B3" value="47.4" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery Asberg Depression Scale (MADRS) With a Score of 13 or Higher</title>
        <description>Clinically relevant depression (MADRS score of 13 or higher) during antiviral treatment presented as &quot;percentage of participants&quot; with &quot;MADRS scores &gt; 13&quot; (entire time period: from starting study medication until end of antiviral treatment = 48 weeks in patients with genotype 1 or 4 and 24 weeks for patients with genotype 2 or 3)</description>
        <time_frame>50 weeks for genotypes 1 or 4 and 26 weeks for patients with genotype 2 or 3</time_frame>
        <population>The final analysis included only patients who received at least one of escitalopram or placebo. Between group differences for the primary outcome parameters were calculated with a chi-square test. For the primary end point (MADRS score of 13 or higher), we treated missing MADRS assessments by multiple imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>After the preobservation period, patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
Peginterferon alfa-2a :
Escitalopram :
Ribavirin :</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
Peginterferon alfa-2a :
Placebo :
Ribavirin :</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Scale (MADRS) With a Score of 13 or Higher</title>
          <description>Clinically relevant depression (MADRS score of 13 or higher) during antiviral treatment presented as &quot;percentage of participants&quot; with &quot;MADRS scores &gt; 13&quot; (entire time period: from starting study medication until end of antiviral treatment = 48 weeks in patients with genotype 1 or 4 and 24 weeks for patients with genotype 2 or 3)</description>
          <population>The final analysis included only patients who received at least one of escitalopram or placebo. Between group differences for the primary outcome parameters were calculated with a chi-square test. For the primary end point (MADRS score of 13 or higher), we treated missing MADRS assessments by multiple imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="21" upper_limit="43"/>
                    <measurement group_id="O2" value="59" lower_limit="48" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Without Depression (Defined as a MADRS Score of 13 or Higher)</title>
        <description>Number of patients who did not develop at any time of antiviral treatment (up to 48 weeks) a MADRS score of 13 or more as a sign of clinically relevant depression</description>
        <time_frame>Patients free of depression during 24 or 48 weeks of antiviral therapy</time_frame>
        <population>Number of patients per group who did not develop any depressive episode during 48 weeks of antiviral therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
Peginterferon alfa-2a :
Escitalopram :
Ribavirin :</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
Peginterferon alfa-2a :
Placebo :
Ribavirin :</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Without Depression (Defined as a MADRS Score of 13 or Higher)</title>
          <description>Number of patients who did not develop at any time of antiviral treatment (up to 48 weeks) a MADRS score of 13 or more as a sign of clinically relevant depression</description>
          <population>Number of patients per group who did not develop any depressive episode during 48 weeks of antiviral therapy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Depression Defined by Diagnostic and Statistical Manual IV (DSM-IV) Criteria</title>
        <time_frame>major depression during 24 or 48 weeks of antiviral therapy</time_frame>
        <population>The final analysis included only patients who received at least 1 dose of escitalopram or placebo. Between-group differences for the secondary outcome parameters were calculated with a chi-square test.</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
Peginterferon alfa-2a :
Escitalopram :
Ribavirin :</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
Peginterferon alfa-2a :
Placebo :
Ribavirin :</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Depression Defined by Diagnostic and Statistical Manual IV (DSM-IV) Criteria</title>
          <population>The final analysis included only patients who received at least 1 dose of escitalopram or placebo. Between-group differences for the secondary outcome parameters were calculated with a chi-square test.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="15"/>
                    <measurement group_id="O2" value="17" lower_limit="12" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Depression Defined as a MADRS Score of 25 or Higher</title>
        <time_frame>severe depression during 24 or 48 weeks of antiviral therapy</time_frame>
        <population>The final analysis included only patients who received at least 1 dose of escitalopram or placebo. Between-group differences for the secondary outcome parameters were calculated with a chi-square test.</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
Peginterferon alfa-2a :
Escitalopram :
Ribavirin :</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
Peginterferon alfa-2a :
Placebo :
Ribavirin :</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Depression Defined as a MADRS Score of 25 or Higher</title>
          <population>The final analysis included only patients who received at least 1 dose of escitalopram or placebo. Between-group differences for the secondary outcome parameters were calculated with a chi-square test.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.3" upper_limit="6"/>
                    <measurement group_id="O2" value="12" lower_limit="7" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life (HRQOL) Measured by the Short Form 36 (SF-36)</title>
        <time_frame>assessed 2,4,12,24 and 48 weeks of antiviral treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Virologic Response</title>
        <description>(negative Polymerase Chain Reaction (PCR) 6 months after the end of antiviral treatment)</description>
        <time_frame>assessed 24 weeks after end of antiviral treatment</time_frame>
        <population>The final analysis included only patients who received at least 1 dose of escitalopram or placebo. Between-group differences for the secondary outcome parameters were calculated with a chi-square test.</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
Peginterferon alfa-2a :
Escitalopram :
Ribavirin :</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
Peginterferon alfa-2a :
Placebo :
Ribavirin :</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response</title>
          <description>(negative Polymerase Chain Reaction (PCR) 6 months after the end of antiviral treatment)</description>
          <population>The final analysis included only patients who received at least 1 dose of escitalopram or placebo. Between-group differences for the secondary outcome parameters were calculated with a chi-square test.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="46" upper_limit="66"/>
                    <measurement group_id="O2" value="46" lower_limit="37" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability</title>
        <time_frame>assessed 2,4,12,24 and for genotype 1 and 4, 48 weeks of antiviral treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <time_frame>assessed 2,4,12,24 and for genotype 1 and 4, 48 weeks of antiviral treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Escitalopram</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>cerebral tumor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>self-harming behavior</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>severe depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Random assignment of patients before the preobservation period followed by patient withdrawal from the trial independent of antidepressant treatment weakens the strength of the randomization.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Dr. Martin Schaefer</name_or_title>
      <organization>Kliniken Essen-Mitte, Department of Psychiatry</organization>
      <phone>+49201-17430001</phone>
      <email>m.schaefer@kliniken-essen-mitte.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

